Federico Longo

2.4k total citations · 1 hit paper
64 papers, 777 citations indexed

About

Federico Longo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Federico Longo has authored 64 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in Federico Longo's work include Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Federico Longo is often cited by papers focused on Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Federico Longo collaborates with scholars based in Spain, United States and France. Federico Longo's co-authors include Fan Jin, Kevin Norwood, Nicolas Penel, Daniel Motola‐Kuba, Do‐Youn Oh, Wilson H. Miller, Aurélien Marabelle, Toshihiko Doi, Philippe A. Cassier and Maya Gottfried and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Federico Longo

61 papers receiving 768 citations

Hit Papers

Pembrolizumab in microsatellite instability high or misma... 2022 2026 2023 2024 2022 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
    2022 240 citations Michele Maio, Paolo A. Ascierto et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Federico Longo Spain 14 500 240 227 160 111 64 777
Yulia Kundel Israel 15 371 0.7× 205 0.9× 276 1.2× 99 0.6× 122 1.1× 54 788
Keijiro Nozawa Japan 18 677 1.4× 246 1.0× 303 1.3× 207 1.3× 201 1.8× 70 1.0k
A Kondi-Pafiti Greece 16 245 0.5× 142 0.6× 255 1.1× 125 0.8× 120 1.1× 76 862
Tine Plato Hansen Denmark 15 429 0.9× 234 1.0× 199 0.9× 266 1.7× 263 2.4× 28 897
Koichi Suyama Japan 12 273 0.5× 157 0.7× 246 1.1× 83 0.5× 159 1.4× 48 706
Joji Yamamoto Japan 17 337 0.7× 156 0.7× 381 1.7× 216 1.4× 171 1.5× 39 997
Ömer Yerci Türkiye 16 281 0.6× 168 0.7× 256 1.1× 120 0.8× 208 1.9× 76 891
J. Kalmus Germany 10 708 1.4× 294 1.2× 103 0.5× 360 2.3× 117 1.1× 22 1.0k
Diana L. Hanna United States 17 600 1.2× 250 1.0× 164 0.7× 182 1.1× 238 2.1× 75 1.0k
Shaobo Mo China 21 506 1.0× 256 1.1× 213 0.9× 132 0.8× 203 1.8× 57 883

Countries citing papers authored by Federico Longo

Since Specialization
Citations

This map shows the geographic impact of Federico Longo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Longo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Longo more than expected).

Fields of papers citing papers by Federico Longo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Longo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Longo. The network helps show where Federico Longo may publish in the future.

Co-authorship network of co-authors of Federico Longo

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Longo. A scholar is included among the top collaborators of Federico Longo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Longo. Federico Longo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marabelle, Aurélien, David M. O’Malley, Andrew Hendifar, et al.. (2025). Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nature Cancer. 6(2). 253–258. 2 indexed citations
2.
3.
Vega‐Piñero, Belén, et al.. (2024). Ready-to-Use Multichamber Bags in Home Parenteral Nutrition for Patients with Advanced Cancer: A Single-Center Prospective Study. Nutrients. 16(3). 457–457. 3 indexed citations
4.
Salgado, María Ángeles Vaz, Víctor Albarrán, Javier Pozas, et al.. (2024). Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer. Future Science OA. 10(1). 2428077–2428077.
5.
6.
Longo, Federico, et al.. (2023). Impact of the COVID-19 Pandemic on Cancer Diagnosis in Madrid (Spain) Based on the RTMAD Tumor Registry (2019–2021). Cancers. 15(6). 1753–1753. 10 indexed citations
7.
Oh, Do‐Youn, Alain P. Algazi, Jaume Capdevila, et al.. (2023). Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study. Cancer. 129(8). 1195–1204. 31 indexed citations
8.
Lorenzen, Sylvie, Thomas J. Ettrich, Federico Longo, et al.. (2023). S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial. ESMO Open. 8(3). 101572–101572. 1 indexed citations
9.
Maio, Michele, Mayur M. Amonkar, Josephine M. Norquist, et al.. (2022). Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study. European Journal of Cancer. 169. 188–197. 7 indexed citations
10.
Longo, Federico, Daniel Castellano, Jérôme Alexandre, et al.. (2022). Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. European Journal of Cancer. 172. 340–348. 14 indexed citations
11.
Losa, Ferrán, Isaura Fernández, L. Iglesias, et al.. (2022). SEOM—GECOD clinical guideline for unknown primary cancer (2021). Clinical & Translational Oncology. 24(4). 681–692. 5 indexed citations
12.
Patel, Manish R., Salvatore Siena, George D. Demetri, et al.. (2020). O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Annals of Oncology. 31. 232–233. 13 indexed citations
13.
Haag, Georg Martin, Sylvie Lorenzen, Thomas J. Ettrich, et al.. (2020). 1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO. Annals of Oncology. 31. S910–S910. 2 indexed citations
14.
Fudio, Salvador, Josep Tabernero, Vivek Subbiah, et al.. (2020). Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis. Cancer Chemotherapy and Pharmacology. 87(1). 113–124. 3 indexed citations
15.
Longo, Federico & Alfredo Carrato. (2020). Ramucirumab treatment in hepatocellular carcinoma. Chinese Clinical Oncology. 9(6). 83–83. 1 indexed citations
16.
Márquez‐Rodas, Iván, Federico Longo, María E. Rodríguez-Ruiz, et al.. (2018). Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. Annals of Oncology. 29. viii732–viii732. 7 indexed citations
17.
18.
Grande, Enrique, Jaume Capdevila, Juan J. Díez, Federico Longo, & Alfredo Carrato. (2013). A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. SHILAP Revista de lepidopterología. 6 indexed citations
19.
20.
Márquez‐Rodas, Iván, Fabiano E. Xavier, Federico Longo, et al.. (2007). Increased expression in calcitonin-like receptor induced by aldosterone in cerebral arteries from spontaneously hypertensive rats does not correlate with functional role of CGRP receptor. Regulatory Peptides. 146(1-3). 125–130. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yulia Kundel Breakdown of academic impact, for papers by Keijiro Nozawa Breakdown of academic impact, for papers by A Kondi-Pafiti Breakdown of academic impact, for papers by Tine Plato Hansen Breakdown of academic impact, for papers by Koichi Suyama Breakdown of academic impact, for papers by Joji Yamamoto Breakdown of academic impact, for papers by Ömer Yerci Breakdown of academic impact, for papers by J. Kalmus Breakdown of academic impact, for papers by Diana L. Hanna Breakdown of academic impact, for papers by Shaobo Mo
Rankless by CCL
2026